ID: ALA2047253

Max Phase: Preclinical

Molecular Formula: C17H12ClFN4

Molecular Weight: 326.76

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc2c(c(Nc3ccc(Cl)cc3F)n1)-c1ccccc1C2

Standard InChI:  InChI=1S/C17H12ClFN4/c18-10-5-6-13(12(19)8-10)21-16-15-11-4-2-1-3-9(11)7-14(15)22-17(20)23-16/h1-6,8H,7H2,(H3,20,21,22,23)

Standard InChI Key:  WHCQIGNZIYEVMT-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 326.76

Molecular Weight (Monoisotopic): 326.0735

AlogP: 4.17

#Rotatable Bonds: 2

Polar Surface Area: 63.83

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.74

CX Basic pKa: 5.93

CX LogP: 4.32

CX LogD: 4.31

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.58

Np Likeness Score: -1.13

References

1. Gangjee A, Zhao Y, Ihnat MA, Thorpe JE, Bailey-Downs LC, Kisliuk RL..  (2012)  Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.,  20  (14): [PMID:22739090] [10.1016/j.bmc.2012.05.068]

2.  (2016)  Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof, 

Source

Source(2):

• Scientific Literature
• BindingDB Database